232,900 Shares in Immatics (NASDAQ:IMTX) Bought by abrdn plc

abrdn plc bought a new position in Immatics (NASDAQ:IMTX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 232,900 shares of the company's stock, valued at approximately $2,657,000. abrdn plc owned approximately 0.28% of Immatics at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. Nan Fung Group Holdings Ltd purchased a new position in Immatics in the 1st quarter worth about $165,000. Affinity Asset Advisors LLC lifted its position in Immatics by 75.0% during the first quarter. Affinity Asset Advisors LLC now owns 350,000 shares of the company's stock valued at $3,678,000 after purchasing an additional 150,000 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Immatics by 38.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company's stock worth $33,899,000 after purchasing an additional 891,191 shares during the last quarter. Baker BROS. Advisors LP raised its stake in Immatics by 10.4% during the 1st quarter. Baker BROS. Advisors LP now owns 6,443,398 shares of the company's stock valued at $67,720,000 after buying an additional 604,545 shares during the last quarter. Finally, Zimmer Partners LP boosted its stake in shares of Immatics by 89.0% in the 1st quarter. Zimmer Partners LP now owns 397,000 shares of the company's stock worth $4,172,000 after buying an additional 187,000 shares during the last quarter. Hedge funds and other institutional investors own 64.41% of the company's stock.

Wall Street Analysts Forecast Growth

IMTX has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Immatics in a report on Thursday, September 5th. Piper Sandler started coverage on shares of Immatics in a research report on Monday, October 7th. They set an "overweight" rating and a $19.00 target price for the company.

Immatics Stock Up 0.2 %

IMTX traded up $0.02 during midday trading on Monday, reaching $9.35. The company had a trading volume of 292,383 shares, compared to its average volume of 488,060. Immatics has a 1 year low of $7.98 and a 1 year high of $13.77. The company has a market cap of $1.12 billion, a P/E ratio of -10.48 and a beta of 0.78. The business has a 50-day moving average of $10.81 and a two-hundred day moving average of $11.35.

Immatics (NASDAQ:IMTX - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.17. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. The company had revenue of $20.19 million during the quarter, compared to analyst estimates of $12.36 million. On average, equities research analysts predict that Immatics will post -0.93 EPS for the current year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.